• Chia-Chi Chen, Teng-Hung Yu, Cheng-Ching Wu, Wei-Chin Hung, Thung-Lip Lee, Wei-Hua Tang, I-Ting Tsai, Fu-Mei Chung, Yau-Jiunn Lee, and Chia-Chang Hsu.
• Department of Pathology, E-Da Hospital, I-Shou University, Kaohsiung 82445 Taiwan.
• Int J Med Sci. 2023 Jan 1; 20 (8): 109110961091-1096.

AbstractBackground: Ficolin-3 (FCN3) is a well-known circulating pattern recognition molecule which plays a role in host immune responses to cancer via activation of the lectin complement pathway. Nevertheless, the clinical significance of FCN3 in patients with hepatocellular carcinoma (HCC) is unclear. Methods: Eighty-seven HCC patients who received hepatectomy at our hospital were included. Immunohistochemical staining was used to assess the FCN3 expression in both tumorous and non-tumorous tissues from the patients, who were classified into high and low expression groups. Differences in clinicopathological characteristics between the two groups were then analyzed. Results: Survival was significantly associated with FCN3 immunohistochemical score (p for trend = 0.048). Kaplan-Meier analysis revealed a higher overall survival rate in the patients with a high FCN3 expression than in those with a low FCN3 expression (p=0.031). A high FCN3 expression in tumor tissue was independently associated with better overall survival (p=0.042). However, multivariate analysis showed that FCN3 expression was not an independent risk factor for overall survival. Conclusion: Our findings suggest that FCN3 is significantly related to the prognosis of HCC. FCN3 may be a prognostic marker in patients with HCC.© The author(s).

20 keywords...

hide…